<DOC>
	<DOCNO>NCT00176852</DOCNO>
	<brief_summary>This study test clinical outcome one two preparative regimen ( determine available donor source ) patient non-malignant hemoglobinopathy . The researcher hypothesize regimen positive effect post transplant engraftment incidence graft-versus-host-disease . Regimen A2 replace Regimen A study . Two patient treat Regimen A evidence initial engraftment thus trigger stop rule arm study .</brief_summary>
	<brief_title>Stem Cell Transplant Hemoglobinopathy</brief_title>
	<detailed_description>Prior transplantation , subject receive either : Cyclophosphamide , Fludarabine , Campath , Total body irradiation ( TBI ) Or Busulfan , Cyclophosphamide , antithymocyte globulin ( ATG ) , granulocyte colony-stimulating factor ( GSCF ) These drug ( radiation ) give help new stem cell take grow . On day transplantation , subject receive stem cell transfuse via intravenous ( IV ) catheter . After stem cell transplantation , subject give cyclosporine-A mycophenolate ( MMF ) /or Methylprednisone/or Methotrexate reduce risk graft-versus-host disease , complication occur donor 's stem cell react patient .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Lipomatosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients Sickle Cell Disease/Thalassemia ( SCD/THAL ) 050 year age acceptable stem cell donor disease characteristic define follow : Stroke , central nervous system ( CNS ) hemorrhage neurologic event lasting longer 24 hour , abnormal cerebral magnetic resonance imaging ( MRI ) cerebral arteriogram MRI angiographic study impair neuropsychological test Acute chest syndrome history recurrent hospitalization exchange transfusion Recurrent vasoocclusive pain 3 episode per year 3 year year recurrent priapism , Impaired neuropsychological function abnormal cerebral MRI scan Stage I II sickle lung disease , Sickle nephropathy ( moderate severe proteinuria glomerular filtration rate [ GFR ] 3050 % predict normal value ) Bilateral proliferative retinopathy major visual impairment least one eye Osteonecrosis multiple joint document destructive change Requirement chronic transfusion red blood cell ( RBC ) alloimmunization &gt; 2 antibody long term transfusion therapy Patients transfusion dependent alpha betathalassemia 035 year age acceptable stem cell donor define criterion section . Patients nonmalignant hematologic disorder transfusiondependent involve potentially lifethreatening cytopenia ( include limit Severe Congenital Neutropenia , DiamondBlackfan Anemia ShwachmanDiamond Syndrome ) 035 year age acceptable stem cell donor Second Transplants Patients sickle cell disease thalassemia fail engraft autologous recovery myeloablative SCT regimen nonmyeloablative regimen eligible protocol . Regimen A2 utilized patient sickle cell disease thalassemia HLAidentical sibling donor patient preexist organ dysfunction make ineligible myeloablative preparative regimen . Regimen B utilized patient sickle cell disease thalassemia HLAidentical sibling donor . Patients must meet criterion . If patient receive prior radiation therapy , eligibility receive additional radiation therapy must determine Dr. Dusenbery If first transplant nonmyeloablative regimen , second transplant occur time If first transplant myeloablative regimen , second transplant must &gt; 6 month first transplant Patients one following : Karnofsky Lansky performance score &lt; 70 Acute hepatitis evidence moderate severe portal fibrosis cirrhosis biopsy Stage IIIIV lung disease GFR &lt; 30 % predict Pregnant lactate female Active serious infection whereby patient intravenous antibiotic one week prior study entry . Any patient AIDS ARC HIV seropositivity Psychologically incapable undergo bone marrow transplant ( BMT ) associate strict isolation document history medical noncompliance Patients able receive total lymphocytic irradiation ( TLI ) due prior radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>high risk hemoglobinopathy</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>donor lymphocyte infusion</keyword>
	<keyword>transfusion dependent</keyword>
	<keyword>stem cell donor</keyword>
	<keyword>cord blood</keyword>
	<keyword>marrow</keyword>
	<keyword>transfusion dependent non-malignant hematologic disorder</keyword>
</DOC>